A.P. Pharma Inc., of Redwood City, Calif., appointed Stephen Davis to its board.

Acorda Therapeutics Inc., of Hawthorne, N.Y., named Arian L. Rabinowicz senior vice president and head of medical affairs.

Adventrx Pharmaceuticals Inc., of San Diego, promoted Brian M. Culley to CEO and Patrick L. Keran to president and chief operating officer. It also appointed Odysseas D. Kostas to its board.

Aldagen Inc., of Durham, N.C., named Richard Kent chairman and appointed James M. Hinson chief medical officer. Tom Amick will serve as president and CEO, while Edward L. Field was named executive vice president and chief business officer.

Alexza Pharmaceuticals Inc., of Mountain View, Calif., promoted Mark K. Oki to vice president of finance and controller.

Amarin Corp. plc, of Dublin, Ireland, appointed Jan van Heek to its board.

Amicus Therapeutics Inc., of Cranbury, N.J., elected John F. Crowley chairman.

Ardea Biosciences Inc., of San Diego, appointed Felix J. Baker to its board.

Aton Pharma inc., of Lawrenceville, N.J., named Michael H. Richardson vice president of commercial operations for the orphan drug business unit and appointed Donald A. Fishbein vice president of commercial operations for the ophthalmic business unit.

Banyan Biomarkers Inc., of Alachua, Fla., appointed Jackson Streeter CEO and chief medical officer.

Benitec Ltd., of Melbourne, Australia, appointed John Chiplin to its board.

BiOasis Technologies Inc., of Vancouver, British Columbia, named Hugh MacNaught executive vice president.

Biogen Idec Inc., of Cambridge, Mass., added John R. Richert as a senior fellow in neurology R&D and added Nancy D. Richert as a fellow in neurology R&D.

Bionovo Inc., of Emeryville, Calif., named Paul Pui-Hay But to its scientific advisory board.

BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., appointed Jeffrey W. Winkelman vice president of oncology programs.

Caliper Life Sciences Inc., of Hopkinton, Mass., named Michael Quail, Vincent Magrini, Patrick Cahill, Christopher Detter, Jan Fang Cheng, John Gill and Karen Beeson to its scientific advisory board.

No Comments